Examples
Worked examples
- Is an instance
MHRA's GCP Inspectorate selects a commercial sponsor for a systems-based inspection under its risk-based compliance programme, reviewing the sponsor's overarching quality management system, pharmacovigilance interface, and vendor oversight rather than any single trial.
- Is an instance
A CRO running site monitoring for a multi-site UK oncology trial is selected for a trial-specific inspection tied to a pending marketing authorisation application, with the inspection scoped to that trial's conduct, monitoring records, and data handling.
- Is an instance
Following a serious breach report, the MHRA conducts a triggered (for-cause) inspection of an investigator site outside the normal risk-based cycle to assess the circumstances directly.
Counter-examples
Looks similar, but isn't
- Not an instance
A routine internal quality assurance audit run by a sponsor's own QA function is not an MHRA GCP inspection -- it is self-inspection, a GCP obligation in its own right, but conducted by the organisation itself rather than by the regulator.
- Not an instance
An MHRA Good Manufacturing Practice (GMP) inspection of a drug manufacturing site is a separate MHRA inspection programme; it assesses manufacturing quality systems, not clinical trial conduct, and falls under different UK legislation from GCP inspections.
Editorial commentary
An MHRA GCP inspection is the UK Medicines and Healthcare products Regulatory Agency’s mechanism for verifying that clinical trials of medicines are conducted, recorded, and reported in accordance with Good Clinical Practice (GCP). The MHRA’s GCP Inspectorate inspects sponsors, contract research organisations (CROs), and investigator sites against the UK’s Clinical Trials Regulations and the ICH E6 GCP guideline, checking that participant rights, safety, and wellbeing were protected and that the resulting trial data are reliable enough to support a marketing authorisation application. It is the UK’s direct counterpart to the FDA’s Bioresearch Monitoring (BIMO) Program in the United States — both are the regulator-run inspection function that sits behind the same underlying ICH GCP standard, applied through each jurisdiction’s own legislative framework.
Who and what gets inspected
MHRA GCP inspections can be directed at any party with GCP obligations under a UK clinical trial:
- Sponsors — inspected for oversight of trial conduct, quality management systems, pharmacovigilance and safety reporting, and vendor/CRO oversight.
- Contract research organisations (CROs) — inspected where trial-related duties have been delegated to them, covering how they carried out monitoring, data management, or other sponsor-delegated functions.
- Investigator sites — inspected for protocol adherence, informed consent, source documentation, and whether what was submitted to the MHRA is supported by what actually happened at the site.
How inspections are selected: risk-based and triggered
The majority of MHRA GCP inspections are carried out under a risk-based compliance programme, which can take two forms:
- Systems-based inspections — assess an organisation’s overarching GCP quality management system rather than any single trial, typically covering sponsors or CROs with an ongoing UK trial portfolio.
- Trial-specific inspections — scoped to a particular trial, often prompted by a pending marketing authorisation application that relies on that trial’s data.
Selection under the risk-based programme weighs factors such as inspection history, the scale and complexity of an organisation’s UK trial activity, and time elapsed since a prior inspection. Outside the routine risk-based cycle, the MHRA also conducts triggered inspections — brought forward in response to a specific concern such as a serious breach report, a whistleblower complaint, or a significant safety signal. These can occur with limited notice.
Finding classifications: critical, major, minor
Observations from an MHRA GCP inspection are documented in an inspection report and classified into one of three severity tiers, broadly consistent with the classification framework used across the shared UK/EU GCP inspectorate community:
- Critical — a significant, unjustified departure from applicable legislative or GCP requirements where there is evidence that participants’ rights, safety, or wellbeing have been or have significant potential to be jeopardised, and/or the trial data are unreliable, and/or a pattern of major non-compliances indicates a systemic quality assurance failure.
- Major — a significant, unjustified departure from requirements that has not (yet) developed into a critical issue but carries the potential to do so if left unaddressed.
- Minor — a departure from applicable requirements, established GCP guidance, or procedural expectations that does not meet the threshold for critical or major.
This three-tier structure mirrors the classification scheme published by the EMA-coordinated GCP inspectors working group that UK inspectors have historically participated in, and it plays a role analogous to the FDA’s own NAI/VAI/OAI outcome classifications under BIMO — both systems exist to communicate inspection severity in a standardised way, though the specific tiers and terminology are not directly interchangeable between the two regulators.
After the inspection
Inspected organisations are expected to respond to the inspection report with a corrective and preventive action (CAPA) plan addressing each finding. Where critical findings or a pattern of serious non-compliance are identified, the case can be escalated within the MHRA’s own governance structure — historically to a GCP Inspection Action Group — which can require enhanced oversight, a re-inspection, or further regulatory action. Persistent or serious non-compliance can affect an organisation’s or investigator’s ability to conduct further UK clinical trials.
Frequently Asked Questions
Is an MHRA GCP inspection the same as an FDA BIMO inspection?
They are the UK and US counterparts of the same underlying function, not the same programme. Both inspect clinical trial sponsors, CROs, and investigator sites against Good Clinical Practice, and both exist to protect participant safety and verify data reliability — but they operate under different national legislation, use different finding-classification schemes (MHRA’s critical/major/minor versus FDA’s NAI/VAI/OAI outcome model under BIMO), and are run by different regulators with no automatic reciprocity between a UK and a US inspection outcome.
What triggers an MHRA GCP inspection outside the routine risk-based cycle?
A triggered (for-cause) inspection can follow a serious breach report, a complaint, a significant safety signal, or another specific concern that prompts the MHRA to inspect outside its normal risk-based schedule. These can be conducted with limited advance notice.
Does a critical finding automatically stop a trial?
Not automatically, but a critical finding reflects evidence that participant safety has been or could be seriously jeopardised, or that trial data are unreliable — outcomes at that severity are escalated within the MHRA and can lead to a range of regulatory responses, up to and including action that affects an organisation’s or investigator’s ability to continue or conduct further UK trials.
Who actually gets inspected — the sponsor, the CRO, or the site?
Any of them, depending on where GCP obligations sit for the trial in question. Systems-based inspections typically target a sponsor’s or CRO’s overarching quality system; trial-specific inspections can extend to the investigator sites involved in that particular trial.
Related CASRAI Resources
- FDA BIMO (Bioresearch Monitoring) Program — the US counterpart inspection programme
- ICH GCP (Good Clinical Practice) — the underlying quality standard both regulators inspect against
- ALCOA+ (Clinical Trial Data Integrity Principles) — the data-integrity framework MHRA and FDA both apply during inspection
- Source Documentation
- Trial Master File (TMF)
- EU Clinical Trials Regulation and CTIS
- Clinical Research Administration — cluster hub
References
- MHRA, Clinical trials for medicines: good clinical practice inspections (GOV.UK)
- MHRA, Responding to a GLP and GCP inspection report (GOV.UK)
- MHRA Inspectorate blog, mhrainspectorate.blog.gov.uk
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="MHRA GCP Inspection"
vocab-term-identifier="https://casrai.org/dictionary/term/mhra-gcp-inspection" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/mhra-gcp-inspection",
"name": "MHRA GCP Inspection",
"identifier": "https://casrai.org/dictionary/term/mhra-gcp-inspection",
"description": "An MHRA GCP inspection is an on-site or remote audit conducted by the UK Medicines and Healthcare products Regulatory Agency's GCP Inspectorate to assess whether a clinical trial sponsor, contract research organisation (CRO), or investigator site is conducting research in compliance with the UK Clinical Trials Regulations and the principles of Good Clinical Practice (GCP) set out in ICH E6. Inspections are the mechanism by which the MHRA verifies that trial data submitted in support of a marketing authorisation can be trusted and that participants' rights, safety, and wellbeing were protected during the conduct of the trial.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
"url": "https://casrai.org/dictionary/term/mhra-gcp-inspection",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-23T06:32:16",
"inLanguage": "en"
}
